Journal of psychopharmacology (Oxford, England)

Using timed drug treatments to improve brain adaptability for depression and other nervous system disorders

Updated

Abstract

Event-driven pharmacology (EDP) may lead to sustained pharmacodynamic effects from transient binding events of plastogens.

  • Plastogens may produce long-lasting changes in neuroplasticity without subjective mental states or may cause such effects along with dissociative symptoms.
  • Neuropsychiatry evidence indicates that plastogens can activate synaptic machinery, enhancing the ability of synapses to respond to future stimuli.
  • Rapid-acting plastogens, such as ketamine and classical psychedelics, are proposed to operate within the EDP model.
  • Traditional drug development models focusing on stable receptor occupancy may not yield durable benefits and could increase side effects.
  • New methodologies for drug development and clinical dosing will be necessary to align with the distinct actions of plastogens.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Declaration of conflicting interestsThe authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: TDG is listed as co-author in patents and patent applications related to the pharmacology and use of (2R,6R)-HNK and other hydroxynorketamines in the treatment of depression and other neuropsychiatric disorders. TDG has served as a consultant for Boehringer Ingelheim during the preceding 3 years but declares no nonfinancial competing interests. SJM has received consultant fees or research support (prior 3 years) from Abbott, Almatica Pharma, Autobahn Therapeutics, Biohaven, BioXcel Therapeutics, Boehringer Ingelheim, Brii Biosciences, Clexio Biosciences, Compass Pathways, Delix Therapeutics, Douglas Pharmaceuticals, EMA Wellness, Engrail Therapeutics, Freedom Biosciences, LivaNova, Merck, Motif Neurotech, Neumora, Neurocrine, Newleos, Perception Neuroscience, Praxis Precision Medicines, Relmada Therapeutics, Sage Therapeutics, Signant Health, Sunovion Pharmaceuticals, Supernus, and Xenon Pharmaceuticals but declares no nonfinancial competing interests. MF has received research support (preceding 3 years) from AbbVie; Acadia Pharmaceuticals; Aditum Bio Management Company, LLC; Alkermes, Inc.; Allergan; Altimate Health Corporation; Alto Neuroscience, Inc.; Ancora Bio, Inc.; Angelini S.p.A; Aptinyx; Arbor Pharmaceuticals LLC; Axsome; Benckiser Pharmaceuticals, Inc.; Bioclinica, Inc.; Biogen; Biohaven; BioShin Limited; Cambridge Science Corporation; Centrexion Therapeutics Corporation; Cybin IRL Limited; Damona Pharmaceuticals; Eliem Therapeutics LTD; EmbarkNeuro; Genomind, LLC; Gentelon, LLC; Gerbera Therapeutics, Inc.; GH Research Ireland Limited; Happify; Johnson & Johnson; Lundbeck Inc.; Marinus Pharmaceuticals; Medpace, Inc.; Millennium Pharmaceuticals, Inc.; Minerva Neurosciences; NeuraWell Therapeutics, Inc.; Neurocrine Biosciences, Inc.; Novaremed; Otsuka; Peachtree BioResearch Solutions, Inc.; Pfizer; Praxis Precision Medicines; Premier Research International; Protagenic Therapeutics, Inc.; Relmada Therapeutics, Inc.; Shenox Pharmaceuticals; Stanley Medical Research Institute (SMRI); Syndeio Biosciences; Takeda; University of Florida Board of Trustees; University of Michigan; Vistagen; WinSanTor, Inc.; Xenon Pharmaceuticals, Inc.; and XWPharma Ltd. but declares no nonfinancial competing interests. AS is founder of biotech companies Anagin, Inc.; Monument Bio; MindX; and Syndeio Biosciences; scientific advisor and stockholder for Karuna Therapeutics and Aardwolf Therapeutics; and scientific advisor for Artemis Pharmaceuticals but declares no nonfinancial competing interests.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free